Viva In Vitro is at the forefront of biomedical research and development, particularly focusing on inflammasomes, with a strong emphasis on the NLRP3 pathway. The company has developed a patented ex vivo assay that allows for the assessment of monocyte behavior, specifically determining whether they are NLRP3-immuno-paralyzed. This innovative technique enables the detection of ASC-specks, which are critical for evaluating the immune status of patients. By providing precise and user-friendly methods for immune status assessment, Viva In Vitro aims to enhance personalized medicine, particularly in the context of sepsis, multiple sclerosis, and other inflammatory diseases.

The company is committed to reducing mortality rates associated with sepsis, which is a leading cause of in-hospital deaths globally. Their initiatives include the development of a sepsis stratification device, VIVA SEPS CARE, which is designed to assist healthcare providers in making timely and effective treatment decisions. With the backing of prestigious institutions and funding from the European Research Council, Viva In Vitro is positioned as a key partner for pharmaceutical and biotechnology companies in developing therapies targeting NLRP3-related conditions. Their ongoing research and development efforts are aimed at improving patient stratification and treatment personalization, ultimately striving to decrease ICU occupancy and healthcare resource consumption.

Spain

International biomedical leaders in inflammasome R&D. Viva In Vitro defines themselves as a cutting-edge and impactful company in the field of research. The company has attracted the confidence of investors and international medical institutions, and has been certified by ENISA as an emerging company within the framework.

Viva In Vitro

Company Details